DLL3 and cancer: Aggregating a cohort of 203,252 tumor samples across 47 cancer types, we found upregulation of DLL3 in the majority of low-grade gliomas (78%), high-grade gliomas (72%), Merkel cell carcinomas (83%), medulloblastomas (69%), and melanomas (43%), in conjunction with SCLCs (89%) and NETs (49%; Fig. 2C).